38470-26-7

Usage

Uses

Used in Pharmaceutical Industry:
6-FLUORO-2,3-DIHYDROQUINOLIN-4(1H)-ONE is used as a key intermediate for the development of new drugs and molecules, leveraging its potential biological activities to contribute to the creation of innovative therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 6-FLUORO-2,3-DIHYDROQUINOLIN-4(1H)-ONE serves as a building block in the synthesis of new agrochemicals, potentially enhancing crop protection and management through the development of novel compounds with improved efficacy and selectivity.
Used in Organic Synthesis:
6-FLUORO-2,3-DIHYDROQUINOLIN-4(1H)-ONE is utilized as a valuable intermediate in organic synthesis, providing a foundation for the creation of a wide range of chemical compounds with diverse applications across various industries.
Used in Medicinal Chemistry:
As a component in medicinal chemistry, 6-FLUORO-2,3-DIHYDROQUINOLIN-4(1H)-ONE is employed in the design and synthesis of new pharmaceutical agents, capitalizing on its structural features to develop molecules with targeted biological activities and therapeutic potential.

Upstream product

• 852292-38-7 N-[4-fluoro-2-(3-hydroxy-prop-1-ynyl)-phenyl]-4-methyl-benzenesulfonamide 
• 61272-76-2 4-fluoro-2-iodoaniline 
• 38470-22-3 3-(4-fluorophenylamino)propionic acid 
• 135154-75-5 3-bromo-N-(4-fluorophenyl)propionamide 
• 352-34-1 4-fluoro-1-iodobenzene 
• 371-40-4 4-fluoroaniline 
• 135154-76-6 1-(4-fluorophenyl)azetidin-2-one 
• 71-43-2 benzene 

Downstream Products

• 391-77-5 4-Chloro-6-fluoroquinoline 
• 81892-46-8 6-fluoro-4-oximino-1-propionyl-1,2,3,4-tetrahydroquinoline 
• 890841-79-9 C₁₆H₁₄FNO 

Relevant academic research and scientific papers

2,3-dihydro-1H-quinoline-4-ketone thiosemicarbazone derivatives as well as preparation method and application thereof

The invention discloses 2,3-dihydro-1H-quinoline-4-ketone thiosemicarbazone derivatives as well as a preparation method and application thereof. The structural formula of the derivatives is as shown in a formula (I): (the formula is as shown in the description), wherein R1 is halogen, alkyl or alkoxy; R2 is hydrogen, halogen or alkoxy; R3 is hydrogen or halogen; R4 is hydrogen or halogen; X is hydrogen, acetyl or nitryl; and Y is hydrogen or phenyl. The derivatives can obviously inhibit proliferation of tumor cells, and has significant inhibition effect on multiple cancer cell strains such asbreast cancer cells, melanoma cells and prostatic cancer cells; and the anti-tumor activity is obviously better than that of a broad-spectrum anti-cancer medicine cis-platinum. In addition, the preparation process of the derivatives is simple, the conditions are mild, the sources of the raw materials are rich, the production cost is low, and potential medicinal value and good application prospectin the aspect of preparing a novel anti-tumor medicine are achieved.

Asymmetric Synthesis of Cyclopentene-Fused Tetrahydroquinolines via N-Heterocyclic Carbene Catalyzed Domino Reactions

A new strategy for the N-heterocyclic carbene catalyzed asymmetric synthesis of cyclopentene-fused tetrahydroquinoline derivatives has been developed. The one-pot organocatalytic domino protocol allows a direct entry to the characteristic cyclopenta[ c ]tetrahydroquinoline core of many alkaloids and some potential drugs employing readily available quinolinone and enal substrates in good domino yields and stereoselectivities.

Synthesis of new tricyclic 5,6-dihydro-4H-benzo[b][1,2,4]tri-azolo[1,5-d][1,4]diazepine derivatives by [3+ + 2]-cyclo-addition/rearrangement reactions

Two new series of tricyclic heterocycles, namely 5,6-dihydro-4H-benzo[b][1,2,4]triazolo[1,5-d][1,4]diazepinium salts 10 and the related neutral, free bases 13 were synthesized from 4-acetoxy-1-acetyl-4-phenylazo-1,2,3,4-tetrahydroquinolines 8 and nitriles 9 in the presence of aluminium chloride by the [3+ + 2]-cycloaddition reaction of the in situ generated azocarbenium intermediates 14 followed by a ring-expansion rearrangement. In the rearrangement reaction, the phenyl substituent in the initially formed spiro-triazolium adducts 16 underwent a [1,2]-migration from C(3) to the electron-deficient N(2). This led to the ring expansion from 6-membered piperidine to 7-membered diazepine furnishing the tricyclic 1,2,4-triazole-fused 1,4-benzodiazepines.

Preparation method of 4-chloro-6-fluoroquinoline

The invention discloses a preparation method of 4-chloro-6-fluoroquinoline. The preparation method comprises the steps: with fluoroaniline as a starting material, firstly, carrying out Michael addition reaction with acrylic acid to obtain an intermediate 3-(4-fluoroanilino)propionic acid; followed by, carrying out a condensation cyclization reaction to obtain an intermediate 6-fluoro-2,3-dihydroquinoline-4(1H)-one; and finally, carrying out halogenation and dehydrogenation reaction to obtain 4-chloro-6-fluoroquinoline. The preparation method has the advantages of wide raw material sources and relatively low cost, thereby having relatively low production cost; at the same time, the preparation method has the advantages of relatively short synthesis route and relatively high yield, especially has mild reaction conditions, has no need of special high temperature equipment, and is suitable for industrialized mass production.

Superacid-catalyzed tandem Meyer–Schuster rearrangement/intramolecular hydroamination of o-anilinopropargyl alcohols for the synthesis of 2,3-dihydro-4(1H)-quinolones

A TfOH-catalyzed synthesis of 2,3-dihydro-4(1H)-quinolones from o-anilinopropargyl alcohols was developed. Studies of N-protecting groups and substituents in phenyl rings showed that diverse groups could be applied. By controlling the catalyst loading, o-anilinopropargyl alcohols underwent the expected transformation smoothly to produce N-protected or N-deprotected 2,3-dihydro-4 (1H)-quinolones in good yields. This transformation probably involved a tandem Meyer–Schuster rearrangement/intramolecular hydroamination reaction process.

Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Synthesis of 2,3-dihydro-4(1H)-quinolones and the corresponding 4(1H)-quinolones via low-temperature fries rearrangement of N-arylazetidin-2- ones

N-Arylazetidin-2-ones of the general form 1, which are readily prepared by GoldbergBuchwald-type copper-catalyzed coupling of N-unsubstituted azetidin-2-ones with the relevant aryl halide or using Mitsunobu cyclization processes, undergo smooth Fries-rearrangement in triflic acid at 018°C to give the isomeric 2,3-dihydro-4(1H)-quinolones (2). Dehydrogenation of the latter compounds using 10% Pd on C in 1.0M aqueous sodium hydroxide/propan-2-ol mixtures at ca. 82°C provides the corresponding 4(1H)-quinolones (3).

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY

The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising t

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.